Placeholder Banner

BIO Comments on FDA’s Draft Guidance on Human Gene Therapy for Neurodegenerative Diseases

April 6, 2021

On Tuesday, April 6th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s January 2021 draft industry guidance on “Human Gene Therapy for Neurodegenerative Diseases.” In its comments, BIO stated that while the guidance covers many critical development issues for gene therapies, it is not specific to gene therapies for neurodegenerative diseases, and further requests that the Agency consider the potential impact of this guidance on gene therapy programs outside of neurodegenerative diseases. To this end, BIO encourages the issuance of (1) broad guidance on gene therapies that includes information that is applicable across diseases and (2) publication of focused and brief disease-specific guidance to provide information to Sponsors on disease-specific issues, as appropriate. Since aspects of this guidance may be relevant to cell therapies, BIO recommends that FDA develop a guidance or Q&A document that is quickly and easily updated, and consolidates cell and gene therapy policy with broad applicability into a single document. In the full comment letter, BIO also provides specific comments on the following topics: Gene Therapies and Accelerated Approval, Preclinical Studies, Chemistry Manufacturing and Controls (CMC), and Clinical Studies. 

Download Full Comments Below
BIO Comments on FDA’s Draft Guidance on Human Gene Therapy for Neurodegenerative Diseases
Discover More
On Friday, March 26th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s public meeting announcement titled, “Best Practices for Development and Application of Disease Progression Models.” BIO appreciates that FDA is seeking…
On Wednesday, December 23rd, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s October 2020 public workshop titled, “New Drugs Regulatory Program Modernization: Implementation of the Integrated Assessment of Marketing…
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…